Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2202-2212

  Bigner, Darell D ^a   Brown, Mark T ^a   Friedman, Allan H ^a   Coleman, R Edward ^a   Akabani, Gamal ^a   Friedman, Henry S ^a   Thorstad, Wade L ^a   McLendon, Roger E ^a   Bigner, Sandra H ^a   Zhao, Xiao Guang ^a   Pegram, Charles N ^a   Wikstrand, Carol J ^a   Herndon II, James E ^a   Vick, Nicholas A ^a   Paleologos, Nina ^a   Cokgor, Ilkcan ^a   Provenzale, James M ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; MONOCLONAL ANTIBODY 81C6; TENASCIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOSIMETRY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; IRRADIATION; ISOTOPE LABELING; MALE; METASTASIS; NEUROTOXICOLOGY; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE;

EID: 0031801502     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2202     Document Type: Article

References (46)

1. Mahaley MS Jr: Neurooncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy. J Neurooncol 11:85-147, 1991
2. Levin VA, Resser KJ, McGrath L, et al: PCNU treatment for recurrent malignant gliomas. Cancer Treat Rep 68:969-973, 1984
3. Schold SC Jr, Friedman HS, Bigner DD: Therapeutic profile of the human glioma line D-54 MG in athymic mice. Cancer Treat Rep 71:849-850, 1987
4. Walker MD, Strike TA, Sheline GE: An analysis of dose-effect relationship on the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725-1731, 1979
5. Leibel SA, Sheline GE: Tolerance of the central and peripheral nervous system to therapeutic radiation, in Lett JT, Altman K1 (eds): Advances in Radiation Biology. New York, NY, Academic, 1987, pp 257-258
6. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30:907-911, 1980
7. Gaspar LE, Fisher BJ, Macdonald DR, et al: Supratentorial malignant glioma: Patterns of recurrence and implications for external-beam local treatment. Int J Radiat Oncol Biol Phys 24:55-57, 1992
8. Choucair AK, Levin VA, Gutin PH, et al: Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65:654-658, 1986
9. Pasquier B, Pasquier D, N'Goulet A, et al: Extraneural metastases of astrocytomas and glioblastomas: Clinicopathological study of two cases and review of literature. Cancer 45:112-125, 1980
10. Hoffman HJ, Duffner PK: Extraneural metastases of central nervous system tumors. Cancer 56:1778-1782, 1985
11. Newton HB, Rosenblum MK, Walker RW: Extraneural metastases of infratentorial glioblastoma multiforme to the peritoneal cavity. Cancer 69:2149-2153, 1992
12. Miller RA, Oseroff AR, Stratte PE, et al: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62:988-995, 1983
13. Embleton MJ, Rowland GF, Simmonds RG, et al: Selective cytotoxicity against human tumor cells by a vindesine-monoclonal antibody conjugate. Br J Cancer 47:43-49, 1983
14. Jansen FK, Blythman HE, Carriere D, et al: Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 62:185-216, 1982
15. Thorpe PE, Brown ANF, Bremmer JAG Jr, et al: An immunotoxin composed of monoclonal anti-Thy-1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: Potent anti-tumour effects in-vitro and in-vivo. J Natl Cancer Inst 75:151-159, 1985
16. Bourdon MA, Coleman RE, Blasberg RG, et al: Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis. Anticancer Res 4:133-140, 1984
17. Bullard DE, Adams CJ, Coleman RE, et al: In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies. J Neurosurg 64:257-262, 1986
18. 2 fragment delivery to tumor in patients with glioma: Comparison of intracarotid and intravenous administration. Cancer Res 50:4105-4110, 1990
19. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49:2807-2813, 1989
20. Kemshead JT, Papanastassiou V, Coakham HB, et al: Monoclonal antibodies in the treatment of central nervous system malignancies. Eur J Cancer 28:511-513, 1992
21. Jain RK, Baxter LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 48:7022-7032, 1988
22. Bourdon MA, Wikstrand CJ, Furthmayr H, et al: Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43:2796-2805, 1983
23. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase 1 trial results. Clin Cancer Res 2:963-972, 1996
24. Food and Drug Administration: Director OoBRaR Center for Drugs and Biologies: Points to consider in the manufacture and testing of monoclonal antibody products for human use. Food and Drug Administration, Bethesda, MD, 1987
25. Lindmo T, Boven E, Cuttitta F, et al: Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77-89, 1984
26. Courtenay-Luck NS, Epenetos AA, Moore R, et al: Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 46:6489-6493, 1986
27. Akabani G, Hawkins WG, Eckblade MB, et al: Patient specific dosimetry based on quantitative SPECT imaging and three-dimensional discrete fourier transform convolution. J Nucl Med 38:308-314, 1997
28. Sgouros G: Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 34:689-694, 1993
29. Jonckheere AR: A distribution-free k-sample test against ordered alternatives. Biometrika 41:133-145, 1954
30. Terpstra TJ: The asymptotic normality and consistency of Kendall's test against trend, when ties are present in one ranking. Indag Math 14:327-333, 1952
31. Sneed PK, Gutin PH, Larson DA, et al: Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:719-727, 1994
32. Deshmukh A, Scott JA, Palmer EL, et al: Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. Clin Nucl Med 21:720-725, 1996
33. Riva P, Arista A, Tison V, et al: Intralesional radioimmunotherapy of malignant gliomas: An effective treatment in recurrent tumors. Cancer 73:1076-1082, 1994
34. Hopkins K, Chandler C, Bullimore J, et al: A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 34:121-131, 1995
35. 131I monoclonal antibody: Feasibility, pharmacokinetics and dosimetry. Br J Cancer 67:144-151, 1993
36. Murphy-Ullrich JE, Lightner VA, Aukhil I, et al: Focal adhesion integrity is down-regulated by the alternatively spliced domain of human tenascin. J Cell Biol 115:1127-1136, 1991
37. Wikstrand CJ, McLendon RE, Carrel S, et al: Comparative localization of glioma - Reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model. J Neuroimmunol 15:37-56, 1987
38. 123I-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest Radiol 28:488-496, 1993
39. 131I-labeled anti-tenascin monoclonal antibody 81C6. Cancer Res 48:2904-2910, 1988
40. 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res 48:559-566, 1988
41. Leibel SA, Gutin PH, Wara WM, et al: Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 17:1129-1139, 1989
42. Wen PY, Alexander E III, Black PM, et al: Long-term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas. Cancer 73:3029-3036, 1994
43. Cheung NK, Cheung IY, Kanete A: Antibody response to murine anti-GD2 monoclonal antibodies: Correlation with patient survival. Cancer Res 54:2228-2233, 1994
44. Walker MD, Alexander EA III, Hunt WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic glioma. J Neurosurg 49:333-343, 1978
45. Brem H, Piantadosi S, Burger PC, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012, 1995
46. Shrieve DC, Alexander E III, Wen PY, et al: Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36:275-284, 1995